Tenaya Therapeutics Inc (TNYA)
$2.3
Performance
- $2.21$2.41$2.30
3.91%
Downside
Day's Volatility :8.3%
Upside
4.56%
- $1.66$7.01$2.30
27.83%
Downside
52 Weeks Volatility :76.32%
Upside
67.19%
Returns
| Period | Tenaya Therapeutics Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -38.56% | 0.0% |
6 Months | -58.15% | 0.0% |
1 Year | -29.14% | 0.0% |
3 Years | -90.41% | -20.6% |
Highlights
Market Capitalization | 182.2M |
Book Value | $1.7 |
Earnings Per Share (EPS) | -1.53 |
Wall Street Target Price | 19.43 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -41.33% |
Return On Equity TTM | -74.54% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -118.3M |
Diluted Eps TTM | -1.53 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.49 |
EPS Estimate Next Year | -1.56 |
EPS Estimate Current Quarter | -0.39 |
EPS Estimate Next Quarter | -0.39 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 744.78%
Technicals Summary
Sell
Neutral
Buy
Tenaya Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Tenaya Therapeutics Inc | -15.07% | -58.15% | -29.14% | -90.41% | -84.95% |
 Regeneron Pharmaceuticals, Inc. | 0.93% | 17.32% | 35.75% | 73.95% | 298.81% |
 Novo Nordisk A/s | 0.96% | -0.08% | 31.44% | 163.47% | 428.79% |
 Alnylam Pharmaceuticals, Inc. | -8.66% | 65.51% | 21.14% | 30.19% | 192.84% |
 Vertex Pharmaceuticals Incorporated | 0.75% | 12.92% | 34.78% | 148.18% | 173.67% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Tenaya Therapeutics Inc | NA | NA | NA | -1.49 | -0.75 | -0.41 | NA | 1.7 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Tenaya Therapeutics Inc | Buy | $182.2M | -84.95% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 298.81% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 428.79% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 192.84% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 173.67% | 32.84 | -4.74% |
Insights on Tenaya Therapeutics Inc
Vs VRTX
In the last 1 year, Vertex Pharmaceuticals Incorporated has given 36.4% return, outperforming this stock by 61.9%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 148.2% return, outperforming this stock by 238.6%
Institutional Holdings
Column Group LLC
11.92%RA Capital Management, LLC
9.66%Casdin Capital, LLC
8.53%BlackRock Inc
5.16%T. Rowe Price Associates, Inc.
4.45%Vanguard Group Inc
4.01%
Company Information
tenaya therapeutics is a privately-held biopharmaceutical company backed by the column group. the company was founded in 2016 by world-leading scientists from the gladstone institute’s cardiovascular division and the university of texas southwestern medical center. tenaya is dedicated to addressing heart failure through multipronged efforts that target the fundamental cellular pathologies present in diseased cardiac muscle and that leverage cutting-edge research in cardiac development and regeneration. tenaya has a lead gene therapy program focused on in vivo reprogramming of cardiac fibroblasts to cardiomyocytes to regenerate heart tissue, and additional programs focused on cardiomyopathies.
Organization | Tenaya Therapeutics Inc |
Employees | 140 |
CEO | Mr. Faraz Ali M.B.A. |
Industry | Miscellaneous |
Discover More
A Spac I Acquisition Corp
$2.30
-4.56%
Keyarch Acquisition Corp
$2.30
-4.56%
Connexa Sports Technologies Inc
$2.30
-4.56%
Us Value Etf
$2.30
-4.56%
First Wave Biopharma Inc
$2.30
-4.56%
Global X Msci Next Emerging
$2.30
-4.56%
Fat Projects Acquisition Corp
$2.30
-4.56%
Capital Link Global Fintech
$2.30
-4.56%
Applied Uv Inc
$2.30
-4.56%